BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form F-1
BIOLINERX LTD. filed this Form F-1 on 09/24/2010
Document Outline
Entire Document (9440.6 KB)
Subdocument 1 - F-1
Page 1 - As filed with the Securities and Exchange Commission on September 24, 2010.
Page 2 - Neither the U.S. Securities and Exchange Commission, the Israel Securities Authority nor any state o
Page 3 - N/A
Page 4 - N/A
Page 5 - This summary highlights selected information contained elsewhere in this prospectus that we consider
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - The following table is a summary of our historical consolidated financial data, which is derived fro
Page 13 - N/A
Page 14 - You should carefully consider the risks we describe below, in addition to the other information set
Page 15 - If we or our licensees are unable to obtain U.S. and/or foreign regulatory approval for our therapeu
Page 16 - We depend on out-licensing arrangements to develop, market and commercialize our therapeutic candida
Page 17 - If we are unable to enter into agreements with third parties to develop, market and commercialize ou
Page 18 - Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of ea
Page 19 - We rely on third parties to conduct our clinical trials and provide other services, and those third
Page 20 - We currently depend on third-party manufacturers to produce our preclinical and clinical therapeutic
Page 21 - We depend on our ability to identify and in-license technologies and therapeutic candidates.
Page 22 - Our business could suffer if we are unable to attract and retain key employees.
Page 23 - We could be adversely affected if healthcare reform measures substantially change the market for med
Page 24 - Our business has a substantial risk of clinical trial and product liability claims. If we are unable
Page 25 - We deal with hazardous materials and must comply with environmental, health and safety laws and regu
Page 26 - Patent protection for our products is important and uncertain.
Page 27 - If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary i
Page 28 - We may be subject to other patent-related litigation or proceedings that could be costly to defend a
Page 29 - We may be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 201
Page 30 - Future sales of our ordinary shares could reduce the market price of our ordinary shares.
Page 31 - Investors in this offering will immediately experience substantial dilution in net tangible book val
Page 32 - Our ordinary shares will be traded on more than one market and this may result in price variations.
Page 33 - As a foreign private issuer, we are permitted to follow certain home country corporate governance pr
Page 34 - We conduct our operations in Israel and therefore our results may be adversely affected by political
Page 35 - We have received Israeli government grants and loans for the operation of a biotechnology incubator
Page 36 - Provisions of Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of
Page 37 - Your rights and responsibilities as a shareholder will be governed by Israeli law which may differ i
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - The following table sets forth our selected consolidated financial data for the periods ended and as
Page 46 - You should read the following discussion of our financial condition and results of operations in con
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - N/A
Page 54 - N/A
Page 55 - N/A
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - N/A
Page 63 - N/A
Page 64 - N/A
Page 65 - Schizophrenia
Page 66 - Clinical and Preclinical Results
Page 67 - N/A
Page 68 - N/A
Page 69 - Acute Myocardial Infarction.
Page 70 - Skin Lesions
Page 71 - Neuropathic Pain
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - Patents
Page 81 - Trade Secrets
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - Mutual Recognition and Decentralized Procedures.
Page 93 - Full Applications.
Page 94 - N/A
Page 95 - N/A
Page 96 - Research and Development Grants
Page 97 - Biotechnology Incubator Program
Page 98 - Kinneret Savitsky, Ph.D.,
Page 99 - Leah Klapper, Ph.D.,
Page 100 - Michael J. Anghel, Ph.D.,
Page 101 - N/A
Page 102 - N/A
Page 103 - N/A
Page 104 - N/A
Page 105 - N/A
Page 106 - N/A
Page 107 - N/A
Page 108 - Chairman of the Board.
Page 109 - N/A
Page 110 - N/A
Page 111 - N/A
Page 112 - N/A
Page 113 - Disclosure of Personal Interests of Controlling Shareholders.
Page 114 - N/A
Page 115 - N/A
Page 116 - The following is a description of some of the transactions with related parties to which we, or our
Page 117 - N/A
Page 118 - N/A
Page 119 - N/A
Page 120 - N/A
Page 121 - N/A
Page 122 - N/A
Page 123 - N/A
Page 124 - N/A
Page 125 - N/A
Page 126 - N/A
Page 127 - The following description is not intended to constitute a complete analysis of all tax consequences
Page 128 - Taxation of Non-Israeli Shareholders on Receipt of Dividends
Page 129 - Prospective investors should be aware that this summary does not address the tax consequences to inv
Page 130 - Sale, Exchange or Other Disposition of Ordinary Shares.
Page 131 - Mark-to-Market Election.
Page 132 - Default PFIC Rules.
Page 133 - The U.S. federal income tax rules relating to PFICs are complex. U.S. Investors are urged to consult
Page 134 - N/A
Page 135 - N/A
Page 136 - N/A
Page 137 - N/A
Page 138 - N/A
Page 139 - http://www.sec.gov
Page 140 - N/A
Page 141 - The accompanying notes are an integral part of these condensed financial statements.
Page 142 - The accompanying notes are an integral part of these condensed financial statements.
Page 143 - The accompanying notes are an integral part of these condensed financial statements.
Page 144 - The accompanying notes are an integral part of the financial statements.
Page 145 - The accompanying notes are an integral part of the financial statements.
Page 146 - N/A
Page 147 - N/A
Page 148 - N/A
Page 149 - BioLineRx Ltd.
Page 150 - The accompanying notes are an integral part of the financial statements.
Page 151 - The accompanying notes are an integral part of the financial statements.
Page 152 - The accompanying notes are an integral part of the financial statements.
Page 153 - The accompanying notes are an integral part of the financial statements.
Page 154 - The accompanying notes are an integral part of the financial statements.
Page 155 - The accompanying notes are an integral part of the financial statements.
Page 156 - N/A
Page 157 - N/A
Page 158 - Intellectual property
Page 159 - N/A
Page 160 - N/A
Page 161 - N/A
Page 162 - N/A
Page 163 - N/A
Page 164 - N/A
Page 165 - N/A
Page 166 - N/A
Page 167 - N/A
Page 168 - N/A
Page 169 - N/A
Page 170 - N/A
Page 171 - N/A
Page 172 - N/A
Page 173 - N/A
Page 174 - N/A
Page 175 - N/A
Page 176 - a. Measurement of results for tax purposes in accordance with the Income Tax (Inflationary Adjustmen
Page 177 - N/A
Page 178 - N/A
Page 179 - N/A
Page 180 - N/A
Page 181 - N/A
Page 182 - N/A
Page 183 - N/A
Page 184 - N/A
Page 185 - N/A
Page 186 - N/A
Page 187 - N/A
Page 188 - N/A
Page 189 - N/A
Page 190 - N/A
Page 191 - N/A
Page 192 - N/A
Page 193 - N/A
Page 194 - N/A
Page 195 - N/A
Page 196 - N/A
Page 197 - N/A
Subdocument 2 - EX-3.1 - EX-3.(i) - Articles of Incorporation
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Subdocument 3 - EX-4.2 - Instruments defining the rights of security holders
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Subdocument 4 - EX-10.1 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Subdocument 5 - EX-10.2 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Subdocument 6 - EX-10.3 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Subdocument 7 - EX-10.4 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Subdocument 8 - EX-10.5 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Subdocument 9 - EX-10.6 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Subdocument 10 - EX-10.7 - Material contracts
Page 1 - N/A
Subdocument 11 - EX-10.8 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Subdocument 12 - EX-10.9 - Material contracts
Page 1 - N/A
Subdocument 13 - EX-10.10 - Material contracts
Page 1 - N/A
Page 2 - N/A
Subdocument 14 - EX-10.11 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Subdocument 15 - EX-10.12 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Subdocument 16 - EX-10.13 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Subdocument 17 - EX-10.14 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Subdocument 18 - EX-10.15 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Subdocument 19 - EX-10.16 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Subdocument 20 - EX-10.17 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Page 48 - N/A
Page 49 - N/A
Page 50 - N/A
Page 51 - N/A
Page 52 - N/A
Page 53 - N/A
Page 54 - N/A
Page 55 - N/A
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - N/A
Page 60 - N/A
Page 61 - N/A
Page 62 - N/A
Page 63 - N/A
Page 64 - N/A
Page 65 - N/A
Page 66 - N/A
Page 67 - N/A
Page 68 - N/A
Page 69 - N/A
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - N/A
Page 93 - N/A
Page 94 - N/A
Page 95 - N/A
Page 96 - N/A
Page 97 - N/A
Page 98 - N/A
Page 99 - N/A
Page 100 - N/A
Page 101 - N/A
Page 102 - N/A
Page 103 - N/A
Page 104 - N/A
Page 105 - N/A
Page 106 - N/A
Page 107 - N/A
Page 108 - N/A
Page 109 - N/A
Page 110 - N/A
Page 111 - N/A
Page 112 - N/A
Page 113 - N/A
Page 114 - N/A
Page 115 - N/A
Page 116 - N/A
Page 117 - N/A
Page 118 - N/A
Page 119 - N/A
Page 120 - N/A
Page 121 - N/A
Page 122 - N/A
Page 123 - N/A
Page 124 - N/A
Page 125 - N/A
Page 126 - N/A
Page 127 - N/A
Page 128 - N/A
Subdocument 21 - EX-10.18 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Subdocument 22 - EX-10.19 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - N/A
Page 34 - N/A
Page 35 - N/A
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - N/A
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - N/A
Subdocument 23 - EX-10.20 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Subdocument 24 - EX-10.21 - Material contracts
Page 1 - N/A
Page 2 - N/A
Subdocument 25 - EX-10.22 - Material contracts
Page 1 - N/A
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Subdocument 26 - EX-10.24 - Material contracts
Page 1 - N/A
Subdocument 27 - EX-10.25 - Material contracts
Page 1 - N/A
Page 2 - N/A
Subdocument 28 - EX-21.1 - Subsidiaries of the registrant
Page 1 - N/A
Subdocument 29 - EX-23.1 - Consents of experts and counsel
Page 1 - N/A


Interview with Philip Serlin, CEO
December 2016